Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Islet transplantation benefits endure over 10 years

Islet cells

Three-quarters of people who undergo islet transplantation for type 1 diabetes have sustained graft survival with associated improvements in glucose control, insulin requirements, and hypoglycemia incidence 10 years later, research shows.

CGM time in range: A higher standard for an engaged few?

CGM_action

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Latest headlines

10-18-2019 | Ketoacidosis | News

Off-label SGLT2 inhibitor use linked to higher than expected DKA rates

Real-world, off-label sodium–glucose cotransporter 2 inhibitor use is uncommon in people with type 1 diabetes but appears to be associated with a higher than expected rate of diabetic ketoacidosis when compared with clinical trials, US researchers report.

10-16-2019 | Artificial pancreas systems | News

iDCL trial shows sustained time in range improvement with hybrid closed-loop delivery

People with type 1 diabetes using the Tandem Control-IQ hybrid closed-loop insulin delivery system spent significantly more time within their target blood glucose range than people using a sensor-augmented insulin pump during 6 months of use in the iDCL trial.

10-16-2019 | Islet transplantation | Highlight | News

Islet transplantation benefits endure over 10 years

Three-quarters of people who undergo islet transplantation for type 1 diabetes have sustained graft survival with associated improvements in glucose control, insulin requirements, and hypoglycemia incidence 10 years later, research shows.

Features and expert interviews

10-16-2019 | Continuous glucose monitoring | Feature | Article

CGM time in range: A higher standard for an engaged few?

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

09-24-2019 | Type 2 diabetes | Podcast | Article

How was it for you? The experts discuss EASD 2019

Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

07-24-2019 | Artificial pancreas systems | Feature | Article

Adaptive and flexible: Closed-loop technology for all

medwireNews talks to one of the pioneers of closed-loop insulin delivery, Roman Hovorka, about his algorithm, his research so far, and his plans for commercialization.

Image Credits